Table 2.

Analysis of immune biomarkers in LGD and HGD areas of Intraductal papillary mucinous neoplasm in the training set.

	Isolated LGD areas of LG-IPMN		Progressive LGD areas of HG-IPMN		HGD areas of HG-IPMN
Phenotype	Median	SD	Median	SD	Median	SD	P a
Dysplastic epithelial compartment
CD3+ (n/mm2)	329	210	99	211	140	120	0.017
CD3+CD8+ (n/mm2)	38	86	9	104	13	53	0.047
CD3+PD1+ (n/mm2)	0	4	0	9	0	2	0.800
CD68+ (n/mm2)	10	35	22	34	12	29	0.910
CD68+PD-L1+ (%)	22	30	27	33	25	20	0.658
CD20+ (n/mm2)	2	4	0	3	0	4	0.030
CD45RO+ (n/mm2)	188	83	62	79	63	81	0.008
CD57+ (n/mm2)	23	63	40	88	17	47	0.734
Granzyme B+ (n/mm2)	95	42	34	74	37	61	0.022
FOXP3+ (n/mm2)	2	2	1	7	0	6	0.580
Stromal compartment
CD3+ (n/mm2)	588	676	684	650	659	891	0.971
CD3+CD8+ (n/mm2)	210	321	194	246	130	185	0.610
CD3+PD1+ (n/mm2)	7	45	4	64	9	27	0.521
CD68+ (n/mm2)	97	114	204	252	210	169	0.296
CD68+PD-L1+ (%)	28	24	32	24	36	18	0.998
CD20+ (n/mm2)	23	299	14	38	7	87	0.579
CD45RO+ (n/mm2)	784	536	607	520	547	585	0.659
CD57+ (n/mm2)	76	208	89	105	78	75	0.931
Granzyme B+ (n/mm2)	348	473	320	333	241	288	0.816
FOXP3+ (n/mm2)	24	24	12	75	19	31	0.733
Dysplastic epithelial and stroma compartment
CD3+ (n/mm2)	521	487	474	447	470	308	0.724
CD3+CD8+ (n/mm2)	172	234	133	197	63	138	0.545
CD3+PD1+ (n/mm2)	4	31	2	18	7	12	0.372
CD68+ (n/mm2)	64	69	91	98	146	108	0.300
CD68+PD-L1+ (%)	28	23	31	25	36	18	0.999
CD20+ (n/mm2)	14	149	9	26	5	20	0.370
CD45RO+ (n/mm2)	495	324	321	372	347	301	0.277
CD57+ (n/mm2)	63	113	82	101	47	62	0.926
Granzyme B+ (n/mm2)	250	287	190	238	167	188	0.576
FOXP3+ (n/mm2)	15	14	7	48	10	16	0.787

Abbreviations: HGD, high-grade dysplasia; HG-IPMN, high-grade intraductal papillary mucinous neoplasm; LG-IPMN, low-grade intraductal papillary mucinous neoplasm; LGD, low-grade dysplasia.

^aKruskal–Wallis.